A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 and 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies.

Trial Profile

A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 and 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Aug 2013

At a glance

  • Drugs AR 67 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Jan 2012 Status changed from recruiting to completed.
    • 20 Jan 2012 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top